A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid

Archives of Dermatology

Volumn 143, Issue 12, 2007, Pages 1536-1542

  Beissert, Stefan ^a   Werfel, Thomas ^b   Frieling, Uta ^a   Böhm, Markus ^a   Sticherling, Michael ^c,d   Stadler, Rudolf ^e   Zillikens, Detlef ^f,g   Rzany, Berthold ^h,i   Hunzelmann, Nicolas ^j   Meurer, Michael ^k   Gollnick, Harald ^l   Ruzicka, Thomas ^m,n   Pillekamp, Hans ^o   Junghans, Volker ^p   Bonsmann, Gisela ^a   Luger, Thomas A ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e KLINIKUM MINDEN   (Germany)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g UNIVERSITY OF LÜBECK   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITY OF COLOGNE   (Germany)

^k DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^l OTTO VON GUERICKE UNIVERSITY   (Germany)

^m HEINRICH HEINE UNIVERSITY   (Germany)

ⁿ UNIVERSITY OF MUNICH   (Germany)

^o UNIVERSITY OF ULM   (Germany)

^p UNIVERSITY OF GÖTTINGEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADJUVANT THERAPY; AGED; ARTHRALGIA; ARTICLE; BLISTER; BULLOUS PEMPHIGOID; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMOEPIDERMAL JUNCTION; DISEASE CONTROL; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; IMMUNOGLOBULIN DEPOSITION; INFECTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; SKIN BIOPSY; SKIN EXAMINATION;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; AZATHIOPRINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MYCOPHENOLIC ACID; PATIENT COMPLIANCE; PEMPHIGOID, BULLOUS; RECURRENCE; REMISSION INDUCTION;

EID: 37249036129     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.12.1536     Document Type: Article

References (34)

1. Korman NJ. Bullous pemphigoid: the latest in diagnosis, prognosis, and therapy. Arch Dermatol. 1998;134(9):1137-1141.
2. Vaillant L, Bernard P, Joly P, et al. Evaluation of clinical criteria for diagnosis of bullous pemphigoid. Arch Dermatol. 1998;134(9):1075-1080.
3. Zillikens D, Wever S, Roth A, Weidenthaler-Barth B, Hashimoto T, Bröcker EB. Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol. 1995;131(8):957-958.
4. Gammon WR, Kowalewski C, Chorzelski TP, Kumar V, Briggaman RA, Beutner EH. Direct immunofluorescence studies of sodium chloride-separated skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. J Am Acad Dermatol. 1990;22(4):664-670.
5. Joly P, Gilbert D, Thomine E, et al. Relationship between the in vivo localization and the immunoblotting pattern of anti-basement membrane zone antibodies in patients with bullous pemphigoid. Arch Dermatol. 1997;133(6):719-724.
6. Diaz LA, Ratrie H III, Saunders WS, et al. Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera: immunolocalization of this protein to the hemidesmosome. J Clin Invest. 1990;86(4):1088-1094.
7. Giudice GJ, Emery DJ, Diaz LA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol. 1992;99(3):243-250.
8. Stanley JR, Tanaka T, Mueller S, Klaus-Kovtun V, Roop D. Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies. J Clin Invest. 1988;82(6):1864-1870.
9. Dreno B, Sassolas B, Lacour P, et al. Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: a comparative multicenter study. Ann Dermatol Venereol. 1993;120(8):518-521.
10. Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321-327.
11. Morel P, Guillaume JC. Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. Ann Dermatol Venereol. 1984;111 (10):925-928.
12. Roujeau JC, Lok C, Bastuji-Garin S, Mhalla S, Enginger V, Bernard P. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol. 1998;134(4):465-469.
13. Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol. 2002;138(7):903-908.
14. Savin JA. The events leading to the death of patients with pemphigus and pemphigoid. Br J Dermatol. 1979;101(5):521-534.
15. Burton JL, Harman RR, Peachey RD, Warin RP. Azathioprine plus prednisone in treatment of pemphigoid. Br Med J. 1978;2(6146):1190-1191.
16. Greaves MW, Burton JL, Marks J, Dawber RP. Azathioprine in treatment of bullous pemphigoid. Br Med J. 1971;1(5741):144-145.
17. Guillaume JC, Vaillant L, Bernard P, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol. 1993;129(1):49-53.
18. Böhm M, Beissert S, Schwarz T, Metze D, Luger T. Bullous pemphigoid treated with mycophenolate mofetil. Lancet. 1997;349(9051):541.
19. Fine JD. Management of acquired bullous skin diseases. N Engl J Med. 1995;333 (22):1475-1484.
20. Fivenson DP, Breneman DL, Rosen GB, Hersh CS, Cardone S, Mutasim D. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol. 1994;130(6):753-758.
21. Grundmann-Kollmann M, Korting HC, Behrens S, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol. 1999;40(6, pt 1):957-960.
22. Krain LS, Landau JW, Newcomer VD. Cyclophosphamide in the treatment of pemphigus vulgaris and bullous pemphigoid. Arch Dermatol. 1972;106(5):657-661.
23. Paul MA, Jorizzo JL, Fleischer AB Jr, White WL. Low-dose methotrexate treatment in elderly patients with bullous pemphigoid. J Am Acad Dermatol. 1994;31(4):620-625.
24. Thivolet J, Barthelemy H, Rigot-Muller G, Bendelac A. Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet. 1985;1(8424):334-335.
25. Abma EM, Blanken R, De Heide LJ. Cushing's syndrome caused by topical steroid therapy for psoriasis. Neth J Med. 2002;60(3):148-150.
26. Nilsson JE, Gip LJ. Systemic effects of local treatment with high doses of potent corticosteroids in psoriatics. Acta Derm Venereol. 1979;59(3):245-248.
27. Siklar Z, Bostanci I, Atli O, Dallar Y. An infantile Cushing syndrome due to misuse of topical steroid. Pediatr Dermatol. 2004;21(5):561-563.
28. Young CA, Williams IR, MacFarlane IA. Unrecognised Cushing's syndrome and adrenal suppression due to topical clobetasol propionate. Br J Clin Pract. 1991;45(1):61-62.
29. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol. 1995;131(2):193-197.
30. Snow JL, Gibson LE. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients. J Am Acad Dermatol. 1995;32(1):114-116.
31. Carter SB, Franklin TJ, Jones DF, et al. Mycophenolic acid: an anti-cancer compound with unusual properties. Nature. 1969;223(5208):848-850.
32. Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant. 2005;5(12):2954-2960.
33. Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation. 2003;76(6):984-988.
34. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation. 2003;76(9):1289-1293.